Activity Report 2018

CIC bioGUNE - Centro de Investigación Cooperativa en Biociencias

 

About Us

flecha abajo-derecha

Mission:

Conducting research of excellence in the field of the life sciences, covering the entire value of R&D&i, including technology transfer and commercial exploitation of the generated scientific results.

flecha derecha-abajo

Strategic Challenges:

  • Research of excellence
  • Technology Transfer
  • Collaboration with RVCTI agents
  • International recognition
  • Training and promotion of research talent
  • Attraction and retention of talent
  • Communication and Outreach
  • Excellence in Management

Strategy:

Commitment to specialization and excellence

flecha derecha-arriba

Competitiveness:

  • Leading infrastructures
  • Human Resources
  • Technical and administrative support
  • Competitive salaries
  • Goal-Fulfillment Incentives
flecha abajo-izquierda

Staff 2018

Staff 2018.12.31: 0 181

Average Age: 0 years

Permanent staff: 0%

Gender distribution

  • 0 55.2% Female
    111
  • 0% Male
    84
  • 0% Lismi
    5
 

195 Total CIC bioGUNE Personnel

  • 0 84% Research
    163
  • 0 16% Administration and services
    32

 

Research distribution by Proffesional Category

    % Woman Man
  Researchers 116 71.2 55 61
  • Principal investigators/Platform Managers 26 16.0 7 19
  • Posdoctoral Researches/Research Assistant 40 24.5 17 23
  • PhD Student 50 30.7 31 19
  Technicians 47 28.8 37 10

Research distribution by Geographic Origin

Research distribution by Geographic Origin

Spain 87
Italy 10
Portugal 1
Austria 2
United Kingdom 1
Holland 1
Albania 1
Germany 2
Czech Republic 1
America 6
Asia 2
  • 0% Spanish
    87 researchers
  • 0% Rest of Europe
    19 researchers
  • 0% America
    7 researchers
  • 0% Asia
    3 researchers

Training

0 Trabajos Fin de Grado

0 Trabajos fin de Máster

0 Erasmus

0 Formación Profesional

0 Prácticas Formativas de Grado

Technology transfer and innovation 2018

New Patent Applications: 0

New Collaboration Agreements: 0

New Research Contracts: 0

0 new Patents:

  • CA 0
  • CA 0

0 Licensing Agreement

Economic Activity: 2.326.057

  • Basque Country: 0%
  • Spain: 0%
  • International: 0%
 

8 New Patent Applications

 
  • 0 European Patent Application
  • 0 PCT Patent Application
  • 0 PTO Patent Application

Funding 2018

Total 2018 R&D Budget: 0 million €

N. R&D Projects: 0

 
  • 0 % Public Funding
  • 0 % Private Funding
  • Total: 0% competitive + 0% non-competitive
  • 0 % Basque Government Departments (Competitive + non competitive)
    6.057 K€
  • 0 % MINECO & MEDC (Spanish Government)
    2.533 K€
  • 0 % R&D Contracts, Research Services & Others
    1.376 K€
  • 0 % EU & International Projects
    1.040 K€

R&D&I good practices

R&D Policy

The CIC bioGUNE R&D policy lays on fundamental pillars of Excellent Research in biosciences and Technology Transfer. Our activities are devoted to generation of knowledge and transfer of technologies to society and centered in specialization and excellence.

Our R&D activities follow central aspects like:

  • High impact of research activities focused on ameliorating wealth of society and framed in the strategic research initiative devoted to the development of the Basque Country
  • Creation and education of young scientific talent and promote career path to fulfill personal and professional development of talent
  • Institutional cooperation at local, national and international level
  • Internationalization and visibility of Center’s activities
  • Promote the knowledge transfer to society and contribute to the economic development and competitiveness of biomedicine and biotechnology industry in the Basque Country
  • Insure diffusion and outreach of scientific knowledge to the society and industry
  • Effective and transparent management of resources to fulfill funding agencies expectation and priorities in the Basque Country.

Norma UNE 166002

27 de Noviembre, 2018

Se ha realizado una auditoría basada en procesos y enfocada a los aspectos significativos, riesgos, objetivos, de acuerdo con la norma de referencia. La auditoría se ha realizado por muestreo y con base a la información disponible en el momento de la auditoría. Los métodos utilizados han sido entrevistas, observación de evidencias, y revisión de la documentación y registros.

El equipo auditor considera que se han cumplido los objetivos de la auditoría y la organización ha establecido y mantenido su sistema de gestión de acuerdo a los requisitos de la norma y demuestra la capacidad del sistema para cumplir eficazmente con los requisitos del producto/servicio para el alcance, objetivos y pollitica de la organización.

Singular Projects

International

Special Networks

Strategic Plan: Bioinformatics

New Projects H2020

European Research Council
Advanced Grant

0 M€

EMA/OD/186/17 (UPI-278)

DRU-2018-6297

FDA

Porphyrias Consortium

With the American Porphyrias Consortium.

Joint effort for the clinical phase trial (I/II) of Ciclopirox for CEP.

Services

Drug toxicity evaluation using CHASSYS™ platform

Billing 2018: 0

Billing 2019: 0

Employment

Staff increase: 0%

Employees: 0

Liquid oral formulation development for the clinical phase trial

2019

FDA

Pre-Investigational New Drug (IND) Meeting

1Q 2020

Scientific Output

 

Publications

 

Citations

First Quartile Q1

First Decil D1

IF > 10

Collaborations RVCTI 2018

Achucarro Basque Center for Neuroscience BC Materials Biocruces Biodonostia Bioef
CIC biomaGUNE Ikerbasque Inbiomed POLYMAT UPV

Highlights

CIC bioGUNE researchers publish more than 150 publications. 17% of them have an Impact Factor above 10. The average IF in 2018 reaches 7,8.

Competitive funding at CIC bioGUNE reaches 66% of total funding.

CIC bioGUNE obtains one new ERC Advanced Grant (RECGLYCANMR) in 2018.

Two new research groups (Computational Biology and Integrative Genomics) join CIC bioGUNE.

CIC bioGUNE is recognized within the top 100 NPO/NGO Institutions worldwide, according to Nature Index.

The NMR facility of CIC bioGUNE is recognized as singular scientific infrastructure (ICTS) in Spain.

CIC bioGUNE obtains the UNE 166002 Quality Accreditation.

CIC bioGUNE and University of Deusto sign a formal agreement to foster training and research on health sciences.

The Scientific Advisory Board of CIC bioGUNE, including Nobel Laureate Richard Henderson, visits our premises for the corresponding evaluation, which is highly positive.

Scientific Highlights

Editorial Activity

  • Joaquín Castilla
    Advisory Board

  • Juan Anguita
    Advisory Board

  • Malu Martínez Chantar
    Editor Board

  • Óscar Millet
    Associate Editor

  • Óscar Millet
    Editor Board

  • Francisco Blanco
    Editor Board

  • Óscar Millet
    Associate Editor

  • Óscar Millet
    Editor Board

  • Edurne Berra
    Associate Editor

  • Jesús Jiménez Barbero
    Editor Board

  • Jesús Jiménez Barbero
    Editor Board

  • Jesús Jiménez Barbero
    Editor Board

  • Juan M. Falcón
    Review Editor

  • Rosa Barrio
    Review Editor

  • Juan Anguita
    Review Editor

  • Juan Anguita
    Review Editor

  • Jesús Jiménez Barbero
    Associate Editor

  • Jesús Jiménez Barbero
    Editor Board

  • Juan Anguita
    Editor Board

  • Rosa Barrio
    Editor Board

  • Félix Elortza
    Associate Editor

  • María Vivanco
    Editor Board

  • Edurne Berra
    Associate Editor

  • Jesús Jiménez Barbero
    Editor Board

  • Jesús Jiménez Barbero
    Editor Board

  • Jesús Jiménez Barbero
    Editor Board

Nature Index

Nature Index 2018 Annual Tables

Scientific Programmes

Metabolism and Cell Signaling in Disease

  • Personalized medicine
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Liver Diseases
  • Rare Diseases
  • Biomarkers for Diagnosis
  • Biomarkers for Prognosis
  • Drug Design and Discovery

Molecular Recognition and Host-Pathogen

  • Rare Diseases
  • Homeostasis
  • Viral Infections
  • Bacterial Infections
  • Prion Disease
  • Tick-Borne Disease
  • Immune Response
  • Drug Design and Discovery

Platforms

  • NMR Spectroscopy
  • Macromolecular Crystallography
  • Electron Microscopy
  • Genome Analysis
  • Proteomics
  • Metabolomics
  • Animal Facility

Metabolism and Cell Signaling in Disease

  • Personalized medicine
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Liver Diseases
  • Rare Diseases
  • Biomarkers for Diagnosis
  • Biomarkers for Prognosis
  • Drug Design and Discovery

Molecular Recognition and Host-Pathogen

  • Rare Diseases
  • Homeostasis
  • Viral Infections
  • Bacterial Infections
  • Prion Disease
  • Tick-Borne Disease
  • Immune Response
  • Drug Design and Discovery

Technological Platforms

  • NMR Spectroscopy
  • Macromolecular Crystallography
  • Electron Microscopy
  • Genome Analysis
  • Proteomics
  • Metabolomics
  • Animal Facility

Generation of
knowledge

Technology
transfer

Commercialization of
results

Scientific Programmes
Research lines

Cancer

Metabolic diseases

Infectious disease

Rare disease

The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry and Biomedicine, with emphasis on Structural, Molecular and Cell Biology. An integrative Bioinfomatic Program extrapolate relevant conclusion from basic science.

Scientific Programmes
Metabolism & Cell Signaling in Disease

Brain

Breast

Colon

Liver

Prostate

  1. Target discovery and evaluation of their therapeutic potential
  2. Cancer and more: Identification of biomarkers with potential diagnostic value
  3. Novel therapies against rare diseases
  4. The molecular basis of fibrosis
  5. Nonalcoholic steatohepatitis

The Research Programmes
Molecular Recognition & Host-Pathogen Interactions

Parasites

Vaccines

Antibiotics

Membrane remodelling

Animal and plant viruses

  1. Bacterial and Viral Infections: Vaccines for human and animal health
  2. Mechanisms of membrane remodelling during microbial invasion and propagation
  3. Plant vaccines and transgenics
  4. Antibiotics research and molecular characterization

The Research Programmes
Technology Platforms

Genome Analysis Platform

Proteomics Platform

Metabolomics Platform

Animal Facility

Antibodies Production

Drug Repositioning & Discovery

Nuclear Magnetic Resonance

Macromolecular Crystallography

Electron Microscopy Platform

Collaboration Models

Services
R&D Collaborations
Consulting

Theses

Codirected RVCTI

0 RVCTI

0 in progress

CIC bioGUNE Advanced Training
November 12-16th 2018

0 Theses under negociation

Infraestructuras Científicas y
Técnicas Singulares (ICTs)

CIC bioGUNE es el nuevo Laboratorio de RMN de Euskadi (LRE), ICTs de RMN

 

 

Convenio Universidad de Deusto

SAB Visit 2018

1st Session

  • Prof. Christian Griesinger, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
  • Prof. Ulrich Günther, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, UK
  • Prof. Nancy Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
  • Prof. Manuel Serrano, Institut de Recerca Biomédica de Barcelona, Spain.

 

  • Prof. Adriano Aguzzi, Institute of Neuropathology, University Hospital of Zurich, Switzerland
  • Prof. Quentin Anstee, Institute of Cellular Medicine, Newcastle University, UK
  • Prof. Tom Blundell, Department of Biochemistry, Univ of Cambridge, UK
  • Prof. Avelino Corma, Instit Tecnología Química, CSIC-UPV, Valencia, Spain
  • Prof. Richard Henderson, MRC Lab Molecular Biology, Cambridge, UK

2nd Session

Awards and Recognitions

  • Real Sociedad Española de Química

    La Real Sociedad Española de Química concede su Medalla de Oro a Jesús Jiménez Barbero.
  •  La Real Sociedad Española de Química concede su Medalla de Oro a Jesús Jiménez Barbero
  • Eusko Jaurlaritza - Gobierno Vasco

    El Gobierno Vasco reconoce la labor desarrollada por el investigador Óscar Millet en CIC bioGUNE
  • El Gobierno Vasco premia a Óscar Millet en CIC bioGUNE
  • Real Sociedad Española de Química

    Alberto Fernández Tejada, Premio Joven Investigador 2018 de la Real Sociedad Española de Química.
  • Alberto Fernández Tejada, Premio Joven Investigador 2018 de la Real Sociedad Española de Química
  • Ilustre Colegio Oficial de Médicos de Álava

    Premio ICOMA de investigación al Dr. Joaquín Castilla
  • Premio ICOMA de investigación al Dr. Joaquín Castilla
  • SEBBM - Fundación Astrazeneca - Doctores Diz Pintado

    Premios al Dr. Arkaitz Carracedo
  • • Joven Investigador Sociedad Española de Bioquímica y Biología Molecular SEBBM
    • Joven Investigador en Oncología Fundación AstraZeneca
    • VII Premio Nacional de Investigación en Cáncer Doctores Diz Pintado
  • Premios a Arkaitz Carracedo - Fundación AstraZeneca
  • Premios a Arkaitz Carracedo - Doctores Diz Pintado
Ganeko Bernardo

Ganeko Bernardo

Premio José Tormo SEBBM 2018
Georgina Ormaza

Georgina Ormaza

Best PhD Thesis, GERMN 2018

Activities 2018

Activities
Lectures

13th Anniversary Lecture

Special Lectures Week

Special Lecture, prof Richard Henderson

Special Lecture, Prof. Ulrich Günther

Christmas Lecture

I Jornada Mujeres y Ciencia

Enfermedades Raras: Con otra miradar

Revista Papel: Las manos que luchan contra la enfermedad más cruel

Activities
Conferences

ISEV 2018 - Barcelona

EACR conference series - Mechanisms to Therapies, innovations in cancer metabolism

7th Iberian Congress on Prions

X Spanish Drug Discovery Network

Final Meeting - Proteostatic Mechanisms in Health and Disease of the COST Action BM1307 PROTEOSTASIS led by CIC bioGUNE held in Athens (Greece)

V reunión del grupo Español de Hipoxia

Bilbo TB Spanish Tuberculosis Meeting

MikrobioGUNE, the 1st Basque Microbiology Meeting

Activities
Courses/workshops/meetings

Glycovax Training Event IV

Applications of Electron Microscopy: Knowledge and facilities in the Basque Country

Image processing for electron microscopy with Sscipion on the cloud by Carlos Óscar Sorzano

Dissemination & Outreach

Dissemination and Outreach
Press clippings

Dissemination and Outreach
We have also participated in...

Dissemination & Outreach
Radio

  • Arkaitz Carracedo “Premio Nacional de Investigación en Cáncer Doctores Piz Pintado” y “Premio AstraZeneca”
  • Joaquín Castilla “Insomnio familiar letal”
  • Hasier Eraña “artículo publicado en PNAS”
  • José M Mato y Marcelo Guerín “Resistencia bacteriana”
  • Juan Anguita “Enfermedad de Lyme”
  • José M. Mato, Luis Liz y Jesús Jiménez Barbero “Consecución de las Avanced Grant”
  • José M Mato, Óscar Millet y Joaquín Castilla “Día de las enfermedades raras”
  • Arkaitz Carracedo y Verónica Torrano “Congreso del Cáncer”
  • José M. Mato “El valor social de la ciencia” y “OWL Metabolics”
  • Retransmisión en directo desde CIC bioGUNE del programa “Hoy por Hoy Bilbao” de la cadena SER.

Dissemination & Outreach
TV

  • Jesús Jiménez Barbero “ERC Advanced Grant”
  • Arkaitz Carracedo “Congreso del Cáncer”
  • Juan Anguita “Informe de ciencia de Ikerbasque”
Download PDF version Previous Report (2017)